Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, with Intravenous GTX-104 Meeting All Endpoints
Acasti Pharma Inc. announced that the top line results of its pharmacokinetic bridging study with IV GTX-104, the Company’s lead drug candidate for the treatment of Subarachnoid Hemorrhage , met all its planned study endpoints.
[British Journal of Pharmacology] In vivo, investigators studied the role of Caspase-11 in several angiogenesis mouse models using Caspase-11 wild-type and knockout mice. In vitro, scientists detected the effects of Caspase-4 on endothelial functions and Notch signaling by depleting or overexpressing Caspase-4 in HUVECs.
[Proceedings of the National Academy of Sciences of the United States of America] Scientists identified the reversible SUMOylation of FGF receptor 1 (FGFR1) as an intrinsic fine-tuned mechanism in coordinating endothelial angiogenic signaling during neovascularization.